# US 10,500,249 B2 · Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,249 B2
- Document ID: US10500249B2
- Status: Granted
- Kind: B2
- Application number: 14/943,752
- Filed: 2015-11-17
- Published: 2016-05-19
- Granted: 2019-12-10
- Earliest claimed: 2014-11-17
- Assignees: Moerae Matrix, Inc.
- Applicants: Moerae Matrix, Inc.
- Inventors: Cynthia Lander; Colleen Brophy
- Web page: https://patentgrep.com/patent/US10500249B2

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof.

## Claims

### Claim 1

A method for reducing progression of a fibrosis in liver tissue, kidney tissue or vascular tissue; treating fibrotic remodeling of the liver tissue, kidney tissue or vascular tissue; or both, in a subject in need thereof, comprising:
administering to the subject a pharmaceutical composition comprising a therapeutic amount of a polypeptide of the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof selected from the group consisting of a polypeptide of the amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 3) and a polypeptide of the amino acid sequence KAFAKLAARLYRKALARQLGVAA (SEQ ID NO: 4), and a pharmaceutically acceptable carrier thereof,
progression of the fibrosis being characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing remodeling in liver tissue, kidney tissue or vascular tissue, wherein the therapeutic amount of the pharmaceutical composition inhibits at least 65% of activity of MK2, MK3, CaMKI, and TrkB, with limited off-target kinase inhibition, and
wherein the therapeutic amount of the polypeptide reduces progression of the fibrosis, treats remodeling of the liver tissue, kidney tissue or vascular tissue due to the fibrosis, or both reduces progression of the fibrosis in liver, kidney or vascular tissue and treats remodeling of the liver tissue, kidney tissue or vascular tissue due to the fibrosis.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the tissue fibrosis is further characterized by an inflammation in the tissue.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the inflammation is an acute or a chronic inflammation.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the inflammation is mediated by at least one cytokine selected from the group consisting of Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin-10 (IL-1β).

### Claim 5 (depends on 1)

The method according to claim 1, wherein the aberrant fibroblast proliferation and extracellular matrix deposition in the tissue is characterized by an aberrant activity of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) in the tissue compared to the activity of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) in the tissue of a normal healthy control subject.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the step of administering occurs orally, intratracheally, parenterally, intravenously, or intraperitoneally.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the additional therapeutic agent is an anti-infective agent.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the anti-infective agent is an antiviral agent.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the antiviral agent is one or more of sofosbuvir, an HCV boosted protease inhibitor, a nonnucleoside NSSB inhibitor, an NS5a inhibitor, ABT-450 with ritonavir, ABT-450 co-formulated with ABT-267, ABT-450 formulated with sofosbuvir, and ribavirin.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the additional therapeutic agent is a glucocorticoid selected from the group consisting of prednisone, budesonide, mometasone furoate, fluticasone propionate, fluticasone furoate, and a combination thereof.

### Claim 12 (depends on 7)

The method according to claim 7, wherein the additional therapeutic agent is an analgesic agent.

### Claim 13 (depends on 7)

The method according to claim 7, wherein the additional therapeutic agent is selected from the group consisting of a purified bovine Type V collagen, an IL-13 receptor antagonist, a protein tyrosine kinase inhibitor, an endothelial receptor antagonist, a dual endothelin receptor antagonist, a prostacyclin analog, an anti-CTGF monoclonal antibody, an endothelin receptor antagonist, AB0024, a lysyl oxidase-like 2 (LOXL2) antibody, a c-Jun N-terminal kinase (JNK) inhibitor, pirfenidone, IFN-γ1b, a human antibody against all three TGF-β isoforms, a TGF-β activation inhibitor, a recombinant human Pentraxin-2 protein (rhPTX-2), a bispecific IL-4/IL-13 antibody, an antibody targeting integrin αvβ6, N-acetylcysteine, sildenafil, a Tumor Necrosis Factor (TNF) antagonist, and a combination thereof.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the carrier is selected from the group consisting of a controlled release carrier, a delayed release carrier, a sustained release carrier, and a long-term release carrier.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the endothelin receptor antagonist is A-selective.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the TNF antagonist is etanercept.